Literature DB >> 8471445

Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective study.

P A Pasanen1, M Eskelinen, K Partanen, P Pikkarainen, I Penttilä, E Alhava.   

Abstract

The serum values of the tumour markers carcinoembryonic antigen (CEA), cancer-associated carboanhydrate antigens CA 50 and CA 242 were evaluated in 193 patients with hepatopancreato-biliary diseases by receiver operating characteristic (ROC) curve analysis in order to compare their diagnostic accuracy in pancreatic cancer (n = 26), and to define optimal cut-off levels for the serum values of these tumour markers in the diagnosis of pancreatic cancer. The ROC analysis showed that all marker tests are considerably sensitive (77-81%) at the specificity level of 80%. The CA 242 test was more sensitive than CEA and CA 50 at high specificity levels (> 0.90) but slightly less sensitive at low specificity levels (< 0.60). The CEA test and CA 50 test performed equally well at high and low specificity levels. According to this study, it would seem optimal to use the cut-off level of 4.1 ng ml-1 for CEA, and the level of 137 U ml-1 for CA 50, since they gave a sensitivity of 77% at the specificity levels of 83% and 84%, respectively. For CA 242 the optimal cut-off level was 21 U ml-1, which gave a sensitivity and specificity of 81%. In conclusion, the results of ROC curve analysis suggest that the CA 242 test has an advantage over CEA and CA 50 because of its higher specificity in pancreatic cancer. In addition, it would seem reasonable to use higher cut-off values than what has been recommended for CEA and CA 50 in the diagnosis of pancreatic cancer, but for CA 242 the recommended cut-off level of 20 U ml-1 seems appropriate.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8471445      PMCID: PMC1968332          DOI: 10.1038/bjc.1993.156

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  13 in total

1.  Circulating carcinoembryonic antigen in pancreatic carcinoma.

Authors:  M H Kalser; J S Barkin; D Redlhammer; A Heal
Journal:  Cancer       Date:  1978-09       Impact factor: 6.860

2.  Serum CA 50 as a tumor marker in pancreatic cancer: a comparison with CA 19-9.

Authors:  C Haglund; P Kuusela; H Jalanko; P J Roberts
Journal:  Int J Cancer       Date:  1987-04-15       Impact factor: 7.396

3.  Carcinoembryonic antigen (CEA) assay. A laboratory adjunct in the diagnosis and management of cancer.

Authors:  H J Hansen; J J Snyder; E Miller; J P Vandevoorde; O N Miller; L R Hines; J J Burns
Journal:  Hum Pathol       Date:  1974-03       Impact factor: 3.466

4.  Monoclonal antibodies against gastrointestinal tumour-associated antigens isolated as monosialogangliosides.

Authors:  L Lindholm; J Holmgren; L Svennerholm; P Fredman; O Nilsson; B Persson; H Myrvold; T Lagergård
Journal:  Int Arch Allergy Appl Immunol       Date:  1983

5.  Serum and pancreatic juice carcinoembryonic antigen in pancreatic and biliary disease.

Authors:  D L Carr-Locke
Journal:  Gut       Date:  1980-08       Impact factor: 23.059

6.  Tumour markers CA 19-9 and CA 50 in digestive tract malignancies.

Authors:  C Haglund; P J Roberts; H Jalanko; P Kuusela
Journal:  Scand J Gastroenterol       Date:  1992       Impact factor: 2.423

7.  Cancer-associated tumour markers CA 19-9 and CA-50 in patients with pancreatic cancer with special reference to the Lewis blood cell status.

Authors:  P Masson; B Pålsson; A Andrén-Sandberg
Journal:  Br J Cancer       Date:  1990-07       Impact factor: 7.640

8.  Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases.

Authors:  P Kuusela; C Haglund; P J Roberts
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

9.  Sensitivity and specificity of CA242 in gastro-intestinal cancer. A comparison with CEA, CA50 and CA 19-9.

Authors:  O Nilsson; C Johansson; B Glimelius; B Persson; B Nørgaard-Pedersen; A Andrén-Sandberg; L Lindholm
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640

10.  Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9.

Authors:  C Haglund; J Lindgren; P J Roberts; P Kuusela; S Nordling
Journal:  Br J Cancer       Date:  1989-12       Impact factor: 7.640

View more
  6 in total

Review 1.  Advances in biomarker research for pancreatic cancer.

Authors:  Kruttika Bhat; Fengfei Wang; Qingyong Ma; Qinyu Li; Sanku Mallik; Tze-Chen Hsieh; Erxi Wu
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

2.  Evaluation of CA 242 as a tumor marker in gallbladder cancer.

Authors:  Surinder Rana; Usha Dutta; Rakesh Kochhar; Satyavati V Rana; Rajesh Gupta; Ravinder Pal; Kapil Jain; Radhika Srinivasan; Birender Nagi; Chander Kant Nain; Kartar Singh
Journal:  J Gastrointest Cancer       Date:  2012-06

3.  Tumour-associated trypsin inhibitor in the diagnosis of pancreatic carcinoma.

Authors:  P A Pasanen; M Eskelinen; K Partanen; P Pikkarainen; I Penttilä; E Alhava
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

4.  The role of CA-242 and CEA in surveillance following curative resection for colorectal cancer.

Authors:  N R Hall; P J Finan; B M Stephenson; D A Purves; E H Cooper
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640

5.  A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score.

Authors:  P A Pasanen; M Eskelinen; K Partanen; P Pikkarainen; I Penttilä; E Alhava
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

6.  E3-ligase Skp2 predicts poor prognosis and maintains cancer stem cell pool in nasopharyngeal carcinoma.

Authors:  Jing Wang; Ying Huang; Zhong Guan; Jia-Liang Zhang; Hong-Kai Su; Wei Zhang; Cai-Feng Yue; Min Yan; Su Guan; Quentin Qiang Liu
Journal:  Oncotarget       Date:  2014-07-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.